-+ 0.00%
-+ 0.00%
-+ 0.00%

B. Riley Securities Maintains Buy on ArriVent BioPharma, Raises Price Target to $45

Benzinga·03/23/2026 16:10:17
Listen to the news
B. Riley Securities analyst Kalpit Patel maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price target from $37 to $45.